

Longjumeau, 24 January 2013

### Net sales up 5.9% in 2012

<i>(in thousands of euros)</i>	2010	2011	2012	% change
<b>Total as of 31 December</b>	<b>158 511</b>	<b>164 544</b>	<b>174 289</b>	<b>5,9%</b>
<i>including Pharmaceutical Synthesis</i>	<i>99 379</i>	<i>102 096</i>	<i>110 001</i>	<i>7,7%</i>
<i>including Fine Speciality Chemicals</i>	<i>59 132</i>	<i>62 448</i>	<i>64 288</i>	<i>2,9%</i>

The Dynaction Group achieved 5.9% growth in consolidated net sales for 2012 compared with 2011.

#### Pharmaceutical Synthesis

Net sales are up 7.7% for 2012 compared with 2011, driven by activities based on proprietary technological platforms.

#### Fine Specialty Chemicals

The Fine Specialty Chemicals business has continued to grow (+2.9% in 2012 versus 2011), despite confirmation of the Fragrance business underperforming.

In view of this increase in sales, it is possible, as of now, to confirm a significant growth in current operating income for 2012 in relation to 2011.

**Next date: 2012 results on 20 February 2013**

#### About Dynaction :

Dynaction is an industrial holding company focused on a unique development pole: Fine Speciality Chemicals, a field of its subsidiary PCAS and in which it holds a majority share of 60.94 %.

